Renal cell carcinoma future or investigational therapies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Renal cell carcinoma Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Renal cell carcinoma from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural history, Complications and Prognosis
Diagnosis
Staging
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Chest X Ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Renal cell carcinoma future or investigational therapies On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Renal cell carcinoma future or investigational therapies All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Renal cell carcinoma future or investigational therapies
CDC on Renal cell carcinoma future or investigational therapies
Renal cell carcinoma future or investigational therapies in the news
Blogs on Renal cell carcinoma future or investigational therapies
Directions to Hospitals Treating Renal cell carcinoma
Risk calculators and risk factors for Renal cell carcinoma future or investigational therapies

Overview

Renal cell carcinoma is the most common form of kidney cancer arising from the renal tubule. It is the most common type of kidney cancer in adults. Other associated genes include TRC8, OGG1, HNF1A, HNF1B, TFE3, RCCP3, and RCC17.

Future or Investigational Therapies

Vaccine

In November 2006, it was announced that a vaccine had been developed and tested with very promising results.(See [2]) The new vaccine, called TroVax, works by harnessing the patient's own immune system to fight the disease. Oxford BioMedica[3]. Further vaccine trials are underway.